Table 2 Changes in SZ patients before and after the treatment

From: Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment

 

SZ before treatment (m±s.d.)

SZ after treatment (m±s.d.)

One-tailed P-value

Weight (kg)

82.00±16.76

83.52±15.93

0.03

TFEQ

   

 Factor 1

8.60±3.83

8.40±3.83

0.32

 Factor 2

5.46±2.69

5.46±2.85

0.27

 Factor 3

4.06±2.84

4.13±3.04

0.27

PANSS, positive

20.80±5.79

18.53±4.95

0.03

PANSS, negative

18.06±4.21

18.53±5.05

0.47

PANSS, general

39.26±9.36

36.53±10.93

0.16

PANSS, total

78.13±15.05

73.60±18.93

0.19

Glucose (mmol l−1)

4.90±0.49

5.05±1.02

0.07

Cholesterol (mmol l−1)

4.31±1.09

4.45±0.54

0.21

Triglyceride (mmol l−1)

1.10±0.74

1.37±0.88

0.03

HDL (mmol l−1)

1.16±0.24

1.17±0.34

0.47

LDL (mmol l−1)

2.65±0.97

2.65±0.54

0.41

Chol LDL

3.98±1.62

4.00±1.22

0.28

Insulin (pmol l−1)

45.06±30.45

74.76±49.72

0.008

Prolactin (μg l−1)

27.98±51.13

16.12±10.33

0.45

Leptin (ng ml−1)

9.17±14.08

11.71±12.9

0.02

Ghrelin (pg ml−1)

1062.46±379.33

989.09±380.85

0.04

  1. Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; PANSS, Positive and Negative Symptoms Scale; SZ, schizophrenic; TFEQ, Three-Factor Eating Questionnaire.
  2. Bold indicates significant differences pre- to post-treatment (P<0.05, one-tailed), measured with Wilcoxon's signed-rank test.
Back to article page